Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy
the ONA take:
Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy without nephrotoxic chemotherapy or ionizing radiotherapy appear to have a low risk for developing significant long-term renal dysfunction, according to a study published last month in the journal Cancer.
Wilms tumor is a malignant tumor of the kidney and is the most common type of kidney cancer in children. The American Cancer Society estimates that there are about 500 new cases of Wilms tumor diagnosed in the United States each year.
For the study, researchers sought to evaluate the impact of partial nephrectomy on long-term renal dysfunction in children with unilateral Wilms tumor who were not treated with nephrotoxic chemotherapy or ionizing radiation.
Results showed that during the 19.6 years of median follow-up, 21.3% of the 75 patients had an estimated glomerular filtration rate (eGFR) <90 mL/minute/1.73m2 and 12.5% had proteinuria. Researchers found that no patients had an eGFR <60 mL/minute/1.73m2 and 6.7% of patients had hypertension.
Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy appear to have low risk for renal dysfunction.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|